These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 19307996)

  • 21. GM-CSF and IL-2 combination as adjuvant therapy in cutaneous melanoma: early results of a phase II clinical trial.
    Elias EG; Zapas JL; Beam SL; Brown SD
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 2):15-8. PubMed ID: 15934495
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Low-dose thalidomide in refractory and relapsing multiple myeloma].
    Radocha J; Maisnar V
    Vnitr Lek; 2007 Feb; 53(2):129-34. PubMed ID: 17419173
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma.
    Andtbacka RH; Kaufman HL; Collichio F; Amatruda T; Senzer N; Chesney J; Delman KA; Spitler LE; Puzanov I; Agarwala SS; Milhem M; Cranmer L; Curti B; Lewis K; Ross M; Guthrie T; Linette GP; Daniels GA; Harrington K; Middleton MR; Miller WH; Zager JS; Ye Y; Yao B; Li A; Doleman S; VanderWalde A; Gansert J; Coffin RS
    J Clin Oncol; 2015 Sep; 33(25):2780-8. PubMed ID: 26014293
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Steroid-sparing properties of sargramostim in patients with corticosteroid-dependent Crohn's disease: a randomised, double-blind, placebo-controlled, phase 2 study.
    Valentine JF; Fedorak RN; Feagan B; Fredlund P; Schmitt R; Ni P; Humphries TJ
    Gut; 2009 Oct; 58(10):1354-62. PubMed ID: 19505878
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical and immunological characteristics of patients with serologic progression of prostate cancer achieving long-term disease control with granulocyte-macrophage colony-stimulating factor.
    Rini BI; Fong L; Weinberg V; Kavanaugh B; Small EJ
    J Urol; 2006 Jun; 175(6):2087-91. PubMed ID: 16697809
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjuvant therapy for melanoma in dogs: results of randomized clinical trials using surgery, liposome-encapsulated muramyl tripeptide, and granulocyte macrophage colony-stimulating factor.
    MacEwen EG; Kurzman ID; Vail DM; Dubielzig RR; Everlith K; Madewell BR; Rodriguez CO; Phillips B; Zwahlen CH; Obradovich J; Rosenthal RC; Fox LE; Rosenberg M; Henry C; Fidel J
    Clin Cancer Res; 1999 Dec; 5(12):4249-58. PubMed ID: 10632367
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Randomized phase II study comparing thalidomide with medroxyprogesterone acetate in patients with metastatic renal cell carcinoma.
    Lee CP; Patel PM; Selby PJ; Hancock BW; Mak I; Pyle L; James MG; Beirne DA; Steeds S; A'Hern R; Gore ME; Eisen T
    J Clin Oncol; 2006 Feb; 24(6):898-903. PubMed ID: 16484699
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immune-stimulating effects of low-dose perioperative recombinant granulocyte-macrophage colony-stimulating factor in patients operated on for primary colorectal carcinoma.
    Mels AK; Statius Muller MG; van Leeuwen PA; von Blomberg BM; Scheper RJ; Cuesta MA; Beelen RH; Meijer S
    Br J Surg; 2001 Apr; 88(4):539-44. PubMed ID: 11298622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations.
    Kirkwood JM; Moschos S; Wang W
    Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2331s-2336s. PubMed ID: 16609054
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Adjuvant GM-CSF improves survival in high-risk stage iiic melanoma: a single-center Study.
    Grotz TE; Kottschade L; Pavey ES; Markovic SN; Jakub JW
    Am J Clin Oncol; 2014 Oct; 37(5):467-72. PubMed ID: 23428946
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antimony plus recombinant human granulocyte-macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous Leishmaniasis ulcers: a randomized, double-blind, placebo-controlled study.
    Santos JB; de Jesus AR; Machado PR; Magalhães A; Salgado K; Carvalho EM; Almeida RP
    J Infect Dis; 2004 Nov; 190(10):1793-6. PubMed ID: 15499535
    [TBL] [Abstract][Full Text] [Related]  

  • 32. START Trial: a pilot study on STimulation of ARTeriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease.
    van Royen N; Schirmer SH; Atasever B; Behrens CY; Ubbink D; Buschmann EE; Voskuil M; Bot P; Hoefer I; Schlingemann RO; Biemond BJ; Tijssen JG; Bode C; Schaper W; Oskam J; Legemate DA; Piek JJ; Buschmann I
    Circulation; 2005 Aug; 112(7):1040-6. PubMed ID: 16087795
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phase II study of biweekly plitidepsin as second-line therapy in patients with advanced malignant melanoma.
    Eisen T; Thomas J; Miller WH; Gore M; Wolter P; Kavan P; Martín JA; Lardelli P
    Melanoma Res; 2009 Jun; 19(3):185-92. PubMed ID: 19436178
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony-stimulating factor.
    Spitler LE; Grossbard ML; Ernstoff MS; Silver G; Jacobs M; Hayes FA; Soong SJ
    J Clin Oncol; 2000 Apr; 18(8):1614-21. PubMed ID: 10764421
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A phase II trial using thalidomide for Langerhans cell histiocytosis.
    McClain KL; Kozinetz CA
    Pediatr Blood Cancer; 2007 Jan; 48(1):44-9. PubMed ID: 16333818
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma.
    Chuah B; Lim R; Boyer M; Ong AB; Wong SW; Kong HL; Millward M; Clarke S; Goh BC
    Acta Oncol; 2007; 46(2):234-8. PubMed ID: 17453375
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and other immunomodulatory therapies for the treatment of infectious diseases in solid organ transplant recipients.
    Page AV; Liles WC
    Curr Opin Organ Transplant; 2008 Dec; 13(6):575-80. PubMed ID: 19060545
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Granulocyte-macrophage colony-stimulating factor inhalation therapy for patients with idiopathic pulmonary alveolar proteinosis: a pilot study; and long-term treatment with aerosolized granulocyte-macrophage colony-stimulating factor: a case report.
    Tazawa R; Nakata K; Inoue Y; Nukiwa T
    Respirology; 2006 Jan; 11 Suppl():S61-4. PubMed ID: 16423274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Thalidomide for the treatment of resistant cutaneous lupus: efficacy and safety of different therapeutic regimens.
    Cuadrado MJ; Karim Y; Sanna G; Smith E; Khamashta MA; Hughes GR
    Am J Med; 2005 Mar; 118(3):246-50. PubMed ID: 15745722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.